Literature DB >> 1864219

Insulin and cardiovascular disease. Paris Prospective Study.

A M Fontbonne1, E M Eschwège.   

Abstract

The Paris Prospective Study is a long-term investigation of coronary heart disease (CHD) risk factors in a large population of working men. The baseline cohort included 7028 men, 6093 who had a 75-g oral glucose tolerance test with measurement of plasma insulin and glucose levels (0 and 2 h) and 125 who were known non-insulin-treated diabetic patients. After a mean follow-up of 11 yr, 126 deaths ascribed to CHD were reported. Major independent predictors of CHD death were blood pressure, smoking, plasma cholesterol level, and fasting and 2-h postload plasma insulin level. Impairment of glucose tolerance, including overt diabetes, did not rank as an independent predictor when other baseline variables were accounted for. In the subset of the baseline cohort who presented with impaired glucose tolerance or diabetes (n = 943), 26 died from CHD during the follow-up. The strongest independent predictor of subsequent CHD death in this subsample with abnormal glucose tolerance was plasma triglyceride level. In view of the accumulating evidence that hyperinsulinemia and hypertriglyceridemia generally occur in the same type of subjects, in relation to insulin resistance and central obesity, the epidemiological findings of the Paris Prospective Study and of other investigations support the hypothesis that a constellation of mild metabolic abnormalities may play a deleterious role with regard to cardiovascular disease risk.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864219     DOI: 10.2337/diacare.14.6.461

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  23 in total

1.  Effect of hepatic glucose production on acute insulin resistance induced by lipid-infusion in awake rats.

Authors:  Ling Li; Gang-Yi Yang
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

Review 2.  Cardiovascular risk and prevention in diabetes mellitus.

Authors:  Aled W Roberts
Journal:  Clin Med (Lond)       Date:  2010-10       Impact factor: 2.659

3.  Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies.

Authors:  J W Yarnell; C C Patterson; D Bainton; P M Sweetnam
Journal:  Heart       Date:  1998-03       Impact factor: 5.994

4.  The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities.

Authors:  S Graci; R Baratta; C Degano; A Luppa; R Vigneri; L Frittitta; V Trischitta
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

Review 5.  Lipid abnormalities in the metabolic syndrome.

Authors:  Eliot A Brinton
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

6.  Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up.

Authors:  A Fontbonne; N Thibult; E Eschwège; P Ducimetière
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

7.  Advantages of the single delay model for the assessment of insulin sensitivity from the intravenous glucose tolerance test.

Authors:  Simona Panunzi; Andrea De Gaetano; Geltrude Mingrone
Journal:  Theor Biol Med Model       Date:  2010-03-18       Impact factor: 2.432

Review 8.  Preventing long term complications. Implications for combination therapy with acarbose.

Authors:  B R Zimmerman
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Drug therapy of postprandial hyperglycaemia.

Authors:  A D Mooradian; J E Thurman
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

10.  Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.

Authors:  F Anfosso; N Chomiki; M C Alessi; P Vague; I Juhan-Vague
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.